Thymocyte selection-associated high mobility box protein regulates T lymphocytes exhaustion in patients with myelodysplastic syndromes by inhibiting PI3K/AKT/mTOR pathway

IF 3.3 4区 医学 Q2 HEMATOLOGY
Haiyue Niu, Mengying Zhang, Mengyuan Liu, Liyan Yang, Liping Yang, Jie Ren, Yating Yu, Yumei Liu, Limin Xing, Zonghong Shao, Huaquan Wang
{"title":"Thymocyte selection-associated high mobility box protein regulates T lymphocytes exhaustion in patients with myelodysplastic syndromes by inhibiting PI3K/AKT/mTOR pathway","authors":"Haiyue Niu,&nbsp;Mengying Zhang,&nbsp;Mengyuan Liu,&nbsp;Liyan Yang,&nbsp;Liping Yang,&nbsp;Jie Ren,&nbsp;Yating Yu,&nbsp;Yumei Liu,&nbsp;Limin Xing,&nbsp;Zonghong Shao,&nbsp;Huaquan Wang","doi":"10.1002/hon.3224","DOIUrl":null,"url":null,"abstract":"<p>Myelodysplastic syndromes (MDS) patients often experience CD8<sup>+</sup>T lymphocytes exhaustion, which plays a crucial role in the development of MDS. However, the specific role of thymocyte selection-associated high mobility box protein (TOX) in the CD8<sup>+</sup>T lymphocytes exhaustion in MDS patients remains unclear. In this study, we investigated the role of TOX in CD8<sup>+</sup>T lymphocytes exhaustion in patients with MDS. The expression of TOX, inhibitory receptors (IRs), and functional molecules in peripheral blood T lymphocytes of MDS patients and normal controls were detected using flow cytometry. Lentiviral transduction was used to create stable TOX-knockdown CD8<sup>+</sup>T lymphocytes, and small interfering RNA (si-RNA) was used to knock down TOX in Jurkat cells. The expression of TOX was found to be significantly higher in CD8<sup>+</sup>T lymphocytes of MDS patients compared to normal controls. This was associated with upregulated IRs and reduced expression of functional molecules such as Granzyme and Perforin. Myelodysplastic syndromes patients with higher TOX expression had poor clinical indicators and shorter survival. Knockdown of TOX using sh-RNA partially reverses the exhausted phenotype and enhances the lethality of CD8<sup>+</sup>T lymphocytes. Moreover, the knockdown of TOX using si-RNA in Jurkat cells improved cell proliferation activity, down-regulated IRs and activated PI3K/AKT/mTOR signaling pathway. TOX promotes the exhaustion of CD8<sup>+</sup>T lymphocytes by inhibiting PI3K/AKT/mTOR pathway, and targeted inhibition of TOX could partially restore the effector functions and activity of CD8<sup>+</sup>T lymphocytes.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematological Oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hon.3224","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Myelodysplastic syndromes (MDS) patients often experience CD8+T lymphocytes exhaustion, which plays a crucial role in the development of MDS. However, the specific role of thymocyte selection-associated high mobility box protein (TOX) in the CD8+T lymphocytes exhaustion in MDS patients remains unclear. In this study, we investigated the role of TOX in CD8+T lymphocytes exhaustion in patients with MDS. The expression of TOX, inhibitory receptors (IRs), and functional molecules in peripheral blood T lymphocytes of MDS patients and normal controls were detected using flow cytometry. Lentiviral transduction was used to create stable TOX-knockdown CD8+T lymphocytes, and small interfering RNA (si-RNA) was used to knock down TOX in Jurkat cells. The expression of TOX was found to be significantly higher in CD8+T lymphocytes of MDS patients compared to normal controls. This was associated with upregulated IRs and reduced expression of functional molecules such as Granzyme and Perforin. Myelodysplastic syndromes patients with higher TOX expression had poor clinical indicators and shorter survival. Knockdown of TOX using sh-RNA partially reverses the exhausted phenotype and enhances the lethality of CD8+T lymphocytes. Moreover, the knockdown of TOX using si-RNA in Jurkat cells improved cell proliferation activity, down-regulated IRs and activated PI3K/AKT/mTOR signaling pathway. TOX promotes the exhaustion of CD8+T lymphocytes by inhibiting PI3K/AKT/mTOR pathway, and targeted inhibition of TOX could partially restore the effector functions and activity of CD8+T lymphocytes.

胸腺细胞选择相关高迁移率盒蛋白通过抑制PI3K/AKT/mTOR途径调节骨髓增生异常综合征患者的T淋巴细胞衰竭。
骨髓增生异常综合征(MDS)患者经常会出现CD8+ T淋巴细胞衰竭,这在MDS的发展过程中起着至关重要的作用。然而,胸腺细胞选择相关高迁移率盒蛋白(TOX)在MDS患者CD8+ T淋巴细胞衰竭中的具体作用仍不清楚。本研究探讨了TOX在MDS患者CD8+ T淋巴细胞衰竭中的作用。采用流式细胞术检测了MDS患者和正常对照组外周血T淋巴细胞中TOX、抑制受体(IRs)和功能分子的表达。慢病毒转导用于产生稳定的TOX敲除CD8+ T淋巴细胞,小干扰RNA(si-RNA)用于敲除Jurkat细胞中的TOX。结果发现,与正常对照组相比,MDS 患者 CD8+ T 淋巴细胞中 TOX 的表达明显升高。这与 IRs 上调以及 Granzyme 和 Perforin 等功能分子表达减少有关。TOX表达较高的骨髓增生异常综合征患者临床指标较差,生存期较短。使用sh-RNA敲除TOX可部分逆转CD8+T淋巴细胞的衰竭表型并提高其致死率。此外,在Jurkat细胞中使用si-RNA敲除TOX可改善细胞增殖活性、下调IRs并激活PI3K/AKT/mTOR信号通路。TOX通过抑制PI3K/AKT/mTOR通路促进CD8+T淋巴细胞衰竭,靶向抑制TOX可部分恢复CD8+T淋巴细胞的效应功能和活性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Hematological Oncology
Hematological Oncology 医学-血液学
CiteScore
4.20
自引率
6.10%
发文量
147
审稿时长
>12 weeks
期刊介绍: Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged: -Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders -Diagnostic investigations, including imaging and laboratory assays -Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases -Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies -Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems. Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信